Kinase inhibitors blocking LRRK2 gain of function are currently considered as potential treatments in PD, suggesting that further studies are warranted to define the molecular mechanisms underpinning the involvement of LKKR2 variants in PD. Here, LRRK2 is linked to Parkinson disease.